You are viewing the site in preview mode

Skip to main content

Table 3 Associations between changes in (hydroxy)methylation and in DAS28 over the first 3 months of therapy

From: Higher baseline global leukocyte DNA methylation is associated with MTX non-response in early RA patients

  ΔMethylation ΔHydroxymethylation
  Biomarkers B (SE) β p B (SE) β p
1 Δ(hydroxy)methylation − 0.50 (0.60) − 0.07 0.403 − 9.32 (19.40) − 0.04 0.632
2 Δ(hydroxy)methylation − 0.68 (0.51) − 0.09 0.182 − 1.55 (16.35) − 0.01 0.925
  DAS28 − 0.51 (0.07) − 0.51 < 0.001 − 0.52 (0.07) − 0.51 < 0.001
  Erythrocyte folate (nmol/L) − 1.00 × 10−3 (2.00 × 10−4) − 0.15 0.027 − 1.00 × 10−3 (2.00 × 10−4) − 0.16 0.024
  BMI (kg/m2) 0.05 (0.03) 0.19 0.005 0.04 (0.02) 0.18 0.008
  Age (years) 0.01 (0.01) 0.10 0.134 0.01 (0.01) 0.11 0.130
  Sex    0.20 (0.17) 0.08 0.240
  Smoking (current) 0.29 (0.17) 0.11 0.086 0.28 (0.17) 0.11 0.101
  ACPA status (positive)     
  Observations   163    161  
  1. Associations were tested using crude univariate models (1) and adjusted for confounders (2). Potential confounders were baseline DAS28 score, baseline erythrocyte folate levels (nmol/L), BMI (kg/m2), age (years), sex, smoking status (current smoker versus former + never smoker), and ACPA status. Only biomarkers that changed the effect size with > 10% were considered confounders. B beta coefficient, SE standard error, β standardized beta coefficient. p < 0.05 was considered significant
\